Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Net Income towards Common Stockholders: 2014-2025

Historic Net Income towards Common Stockholders for vTv Therapeutics (VTVT) over the last 12 years, with Sep 2025 value amounting to -$8.7 million.

  • vTv Therapeutics' Net Income towards Common Stockholders fell 81.85% to -$8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.5 million, marking a year-over-year decrease of 28.21%. This contributed to the annual value of -$18.5 million for FY2024, which is 8.83% up from last year.
  • As of Q3 2025, vTv Therapeutics' Net Income towards Common Stockholders stood at -$8.7 million, which was down 43.86% from -$6.0 million recorded in Q2 2025.
  • vTv Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$1.1 million for Q3 2021, and its period low was -$8.7 million during Q3 2025.
  • For the 3-year period, vTv Therapeutics' Net Income towards Common Stockholders averaged around -$5.3 million, with its median value being -$5.1 million (2025).
  • The largest annual percentage gain for vTv Therapeutics' Net Income towards Common Stockholders in the last 5 years was 51.75% (2021), contrasted with its biggest fall of 538.77% (2021).
  • Over the past 5 years, vTv Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$7.1 million in 2021, then soared by 32.70% to -$4.7 million in 2022, then increased by 26.70% to -$3.5 million in 2023, then dropped by 4.49% to -$3.6 million in 2024, then slumped by 81.85% to -$8.7 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$8.7 million for Q3 2025, versus -$6.0 million for Q2 2025 and -$5.1 million for Q1 2025.